Does ambulation modify venous thromboembolism risk in acutely ill medical patients?

Thrombosis and Haemostasis

Volumn 104, Issue 5, 2010, Pages 955-961

  Amin, Alpesh N ^a   Girard, Frederick ^b   Samama, Meyer M ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

^c HÔTEL DIEU   (France)

Author keywords

Ambulation; Enoxaparin; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ENOXAPARIN; PLACEBO;

ACUTE RESPIRATORY FAILURE; ACUTELY ILL MEDICAL PATIENT; ADULT; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HEART FAILURE; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOBILIZATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEOPLASM; OBESITY; OUTCOME ASSESSMENT; PATIENT; PHLEBOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; THROMBOSIS PREVENTION; VARICOSIS; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; LOGISTIC MODELS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; VENOUS THROMBOEMBOLISM; WALKING;

EID: 78149483787     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-04-0236     Document Type: Article

References (22)

1. Gerotziafas GT, Samama MM. Prophylaxis of venous thromboembolism in medical patients. Curr Opin Pulm Med 2004; 10: 356-365. (Pubitemid 39099930)
2. Deitelzweig S, Lin J, Johnson BH, et al. Prevalence of venous thromboembolism (VTE) in the USA: now and future [abstract OC-WE-018]. J Thromb Haemost 2009; 7 (Suppl 2): 207-208.
3. Piazza G, Fanikos J, Zayaruzny M, et al. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost. 2009; 102: 505-510.
4. Amin AN, Deitelzweig SB. Optimizing the prevention of venous thromboembolism: recent quality initiatives and strategies to drive improvement. Jt Comm J Qual Patient Saf 2009; 35: 558-564.
5. Bergmann JF, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010; 103: 736-748.
6. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
7. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879. (Pubitemid 39096017)
8. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
9. 2005 HCUP Nationwide Inpatient Sample (NIS) Comparison Report. Report # 2008-01. Rockville, MD, Agency for Healthcare Research and Quality, US Department of Health and Human Services; February 22, 2008. Available at: http://www.hcup-us.ahrq.gov/reports/2008-01.pdf. Accessed September 29, 2009.
10. Ham C, York N, Sutch S, et al. Hospital bed utilisation in the NHS, Kaiser Permanente, and the US Medicare programme: analysis of routine data. Br Med J 2003; 327: 1257.
11. DeFrances CJ, Cullen KA, Kozak LJ. National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data. Vital Health Stat 2007; 13: 1-209.
12. Yu HT, Dylan ML, Lin J, et al. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64: 69-76. (Pubitemid 46395711)
13. Amin A, Lin J, Ryan A. VTE prophylaxis across the continuum of care in US medical patients at risk of venous thromboembolism [Abstract]. Blood 2009; 114: 1386.
14. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. Br Med J 2002; 325: 887-890.
15. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346.
16. Amin AN, Stemkowski S, Lin J, et al. Inpatient thromboprophylaxis use in U.S. hospitals: adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. J Hosp Med 2009; 4: E15-21.
17. Pottier P, Hardouin JB, Lejeune S, et al. Immobilization and the risk of venous thromboembolism. A meta-analysis on epidemiological studies. Thromb Res 2009; 124: 468-476.
18. Vasco B, Villalba JC, Lopez-Jimenez L, et al; RIETE Investigators. Venous thromboembolism in nonagenarians. Findings from the RIETE Registry. Thromb Haemost 2009; 101: 1112-1118.
19. Spyropoulos AC, Hussein M, Lin J, et al. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost 2009; 102: 951-957.
20. Paneesha S, McManus A, Arya R, et al.; VERITY Investigators. Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics. Thromb Haemost 2010; 103: 338-343.
21. Vaitkus PT, Leizorovicz A, Cohen AT, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost 2005; 93: 76-79. (Pubitemid 40124258)
22. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15. (Pubitemid 32709732)